These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37783836)

  • 1. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.
    Freedland SJ; Davis M; Epstein AJ; Arondekar B; Ivanova JI
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):327-333. PubMed ID: 37783836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
    Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
    Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
    Sartor O; George D; Tombal B; Agarwal N; Higano CS; Sternberg CN; Miller K; Jiao X; Guo H; Sandström P; Bruno A; Verholen F; Saad F; Shore N
    Future Oncol; 2022 Jan; 18(1):35-45. PubMed ID: 34636627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
    Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
    Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.
    Barata PC; Leith A; Ribbands A; Montgomery R; Last M; Arondekar B; Ivanova J; Niyazov A
    Oncologist; 2023 Sep; 28(9):e737-e747. PubMed ID: 37014097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Urosevic A; Lefebvre P; Pilon D; George DJ
    J Med Econ; 2024; 27(1):201-214. PubMed ID: 38204397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors.
    Shore ND; Laliberté F; Ionescu-Ittu R; Yang L; Mahendran M; Lejeune D; Yu LH; Burgents J; Duh MS; Ghate SR
    Adv Ther; 2021 Aug; 38(8):4520-4540. PubMed ID: 34282527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data.
    Freedland SJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Ryan CJ
    Curr Med Res Opin; 2021 Apr; 37(4):609-622. PubMed ID: 33476184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
    Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
    Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
    Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
    Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.
    Graf RP; Fisher V; Mateo J; Gjoerup OV; Madison RW; Raskina K; Tukachinsky H; Creeden J; Cunningham R; Huang RSP; Mata DA; Ross JS; Oxnard GR; Venstrom JM; Zurita AJ
    Eur Urol; 2022 Jan; 81(1):37-47. PubMed ID: 34716049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
    Flaig TW; Potluri RC; Ng Y; Todd MB; Mehra M
    Cancer Med; 2016 Feb; 5(2):182-91. PubMed ID: 26710718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George DJ
    J Manag Care Spec Pharm; 2024 Jul; 30(7):684-697. PubMed ID: 38950154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
    Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada.
    Shayegan B; Wallis CJD; Malone S; Cagiannos I; Hamilton RJ; Ferrario C; Gotto GT; Basappa NS; Morgan SC; Fernandes R; Morash C; Niazi T; Noonan KL; Rendon R; Osborne B; Park-Wyllie L; Chan KFY; Hotte SJ; Saad F
    Urol Oncol; 2022 May; 40(5):192.e1-192.e9. PubMed ID: 35216890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
    Thibault C; Eymard JC; Birtle A; Krainer M; Baciarello G; Fléchon A; Le Moulec S; Spaeth D; Laguerre B; Caffo O; Deville JL; Beuzeboc P; Hasbini A; Gross-Goupil M; Helissey C; Bennamoun M; Hardy-Bessard AC; Oudard S
    Eur J Cancer; 2018 Jul; 97():41-48. PubMed ID: 29636272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.
    Barata PC; Leith A; Ribbands A; Montgomery R; Last M; Arondekar B; Ivanova J; Niyazov A
    Oncologist; 2023 Sep; 28(9):780-789. PubMed ID: 37014080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.
    George DJ; Sartor O; Miller K; Saad F; Tombal B; Kalinovský J; Jiao X; Tangirala K; Sternberg CN; Higano CS
    Clin Genitourin Cancer; 2020 Aug; 18(4):284-294. PubMed ID: 32057714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
    Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
    JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.